<DOC>
	<DOCNO>NCT00462592</DOCNO>
	<brief_summary>The purpose study compare effect 2 week therapy montelukast , budesonide , combination exercise induce bronchoconstriction ( EIB ) airway inflammation child young adult , regular controller therapy . Inhaled corticosteroid ( ICS ) potent anti-inflammatory agent , effective control improve aspect asthma include attenuation EIB . However , effect ICS monotherapy EIB comparable inferior effect CysLTs modifier alone . This may due lack effect ICS CysLT pathway . As consequence , investigator hypothesize combination ICS CysLT modifier offer great protection EIB either therapy alone . The different class drug may act complementary pathway believe important pathophysiology EIB .</brief_summary>
	<brief_title>Comparison Combination Therapy : Montelukast Inhaled Steroid Exercise Induced Bronchoconstriction</brief_title>
	<detailed_description>The study 2 centre randomise , double blind , placebo control 4-way cross study compare montelukast , budesonide combination exercise-induced bronchoconstriction ( EIB ) . Subjects stable mild moderate asthma , age 8-35 year , controller asthma therapy screen . A maxFEV1 % ≥15 % follow standardized dry air exercise challenge screening ( SC ) follow 1 week run-in ( V-1 ) require qualify . Once qualified , subject return follow day ( V0 ) skin prick test methacholine inhalation test randomise 1 4 treatment sequence . Each treatment give total 14 day 4 week washout . During period , subject attend laboratory 2 occasion , begin end period . Baseline spirometry ; eNO ; EBC perform , follow exercise challenge serial FEV1 eNO measurement 30 minute post exercise post-exercise EBC sputum induction evaluation visit . There total 10 visit duration study approximately 148 day ( 21 week ) . All visit schedule within 2 hour post-run visit ( V1 ) least 8 hour last dose trial medication . Investigational Product , Dose Administration : Montelukast 5mg ( &lt; 15 year ) 10mg ( match placebo ) take 1 tablet even together inhale budesonide turbuhalers 200ug ( match placebo ) take 1 puff morning 1 puff evening . Efficacy EIB : The change pre post treatment exercise-induced maxFEV1 % area curve ( AUC0-30 ) compare 4 period . MaxFEV1 % calculate pre-exercise FEV1 minus post exercise low FEV1 divide pre-exercise FEV1 multiply 100 ; AUC calculate use trapezoidal rule . The protection provide active treatment define pre-treatment maxFEV1 % minus post-treatment maxFEV1 % divide pre-treatment maxFEV1 % x 100 . The proportion subject attain ≥50 % protection compare 4 arm . Efficacy eNO inflammatory parameter measure sputum EBC Changes % absolute count sputum differential cell , eNO inflammatory mediator ( EBC/ sputum ) baseline response exercise compare 4 arm .</detailed_description>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Males female age 835 year stable mildtomoderate asthma ( ATS criterion ) regular controller therapy Prebronchodilator FEV1 predict ≥ 70 % No medical comorbidity Demonstrate maxFEV1 % ≥15 % exercise challenge screen 1 week post runin . Asthma exacerbation respiratory infection within 4 week screen Recent use inhale systemic steroid Immunosuppressives Antihistamines , NSAIDs investigational drug within 30 day Unable reliably perform spirometry exercise challenge Current exsmokers ≥ 10 packyears less 1 month abstinence Contraindications inhale steroid montelukast use .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>exercise-induced bronchoconstriction ( EIB )</keyword>
	<keyword>airway inflammation</keyword>
</DOC>